Boxer Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-506,000
Closed -$1.08M – 33
2024
Q4
$1.08M Hold
506,000
– – 0.09% 52
2024
Q3
$2.2M Hold
506,000
– – 0.11% 59
2024
Q2
$2.36M Hold
506,000
– – 0.12% 51
2024
Q1
$2.57M Hold
506,000
– – 0.13% 51
2023
Q4
$1.42M Hold
506,000
– – 0.07% 45
2023
Q3
$1.45M Sell
506,000
-1,508,858
-75% -$5.56M 0.08% 59
2023
Q2
$10.2M Hold
2,014,858
– – 0.47% 48
2023
Q1
$3.81M Hold
2,014,858
– – 0.19% 57
2022
Q4
$3.63M Hold
2,014,858
– – 0.19% 53
2022
Q3
$3.4M Hold
2,014,858
– – 0.19% 61
2022
Q2
$4.96M Hold
2,014,858
– – 0.31% 51
2022
Q1
$5.58M Hold
2,014,858
– – 0.29% 52
2021
Q4
$10.7M Hold
2,014,858
– – 0.42% 44
2021
Q3
$17M Hold
2,014,858
– – 0.6% 48
2021
Q2
$24.6M Hold
2,014,858
– – 0.87% 34
2021
Q1
$48.9M Hold
2,014,858
– – 1.66% 14
2020
Q4
$64.6M Hold
2,014,858
– – 2.08% 12
2020
Q3
$60.9M Hold
2,014,858
– – 2.1% 11
2020
Q2
$84.9M Hold
2,014,858
– – 3.73% 7
2020
Q1
$50.3M Buy
+2,014,858
New +$61.3M 3.43% 8

Other funds holding BDTX

Boxer Capital Management's BDTX Position: Q1 2025 in Review

Boxer Capital Management sold out of Black Diamond Therapeutics (BDTX) in Q1 2025, closing a stake of 506,000 shares — an estimated $1.08M sold.

Boxer Capital Management first reported a position in BDTX in Q1 2020 and held it in 20 quarters. The position peaked at $84.9M in Q2 2020. 84 funds tracked by Wall St. Rank hold BDTX as of Q1 2025.

  • Boxer Capital Management reported no remaining Black Diamond Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Boxer Capital Management sold 506,000 Black Diamond Therapeutics shares in Q1 2025, an estimated $1.08M.
  • Boxer Capital Management first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 20 quarters.
  • Boxer Capital Management's Black Diamond Therapeutics position peaked at $84.9M in Q2 2020.
  • 84 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2025.

Based on Boxer Capital Management's 13F filing for Q1 2025, filed 15 May 2025.